Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Hold” from analysts, according to recent data from Marketbeat.com. A total of seven research firms are currently covering the stock, with four analysts suggesting a hold and three recommending a buy.
Analysts have set an average one-year price target of $80.60 for the company’s shares. Notably, several brokerages have recently adjusted their projections. On October 21, Oppenheimer lowered its price target from $82.00 to $72.00, while maintaining an “outperform” rating. Similarly, Canaccord Genuity Group revised its target from $100.00 to $88.00 with a “buy” rating noted in a report dated November 7.
In a noteworthy shift, Zacks Research upgraded Prestige Consumer Healthcare from a “strong sell” to a “hold” rating on November 10. On January 30, Jefferies Financial Group cut its price target from $70.00 to $66.00 while sustaining a “hold” rating. Weiss Ratings also reiterated a “hold (c)” rating on January 22.
Institutional Investor Activity
Several large investors have recently modified their holdings in Prestige Consumer Healthcare. AQR Capital Management LLC increased its stake by 11.9% in the first quarter, now owning 30,056 shares valued at $2.56 million after acquiring an additional 3,200 shares. Meanwhile, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings by 4.6%, bringing its total to 29,490 shares valued at $2.54 million.
In a significant move, Goldman Sachs Group Inc. boosted its stake by 28.4%, acquiring an additional 120,965 shares, which increased its total holdings to 546,672 shares worth approximately $46.99 million. Jane Street Group LLC also made a notable increase, with a 204.0% rise in its stake, now holding 104,802 shares valued at $9.01 million. Lastly, Geneos Wealth Management Inc. grew its holdings by 92.8%, holding 559 shares worth $48,000. Currently, institutional investors own approximately 99.95% of the stock.
Company Performance Insights
As of last Friday, shares of NYSE:PBH opened at $66.48. The company boasts a market capitalization of $3.20 billion and a price-to-earnings ratio of 17.59, with a PEG ratio of 2.06 and a beta of 0.43. Additionally, the stock’s 50-day moving average stands at $63.19, while the 200-day moving average is at $64.06. Over the past year, the stock reached a low of $57.25 and a high of $90.04.
On February 5, the company reported its latest quarterly earnings, revealing an earnings per share (EPS) of $1.14, falling short of analysts’ expectations of $1.16 by $0.02. The revenue for the quarter amounted to $283.44 million, also below the estimated $286.93 million. In comparison to the same quarter last year, revenue declined by 2.4%.
Looking ahead, Prestige Consumer Healthcare has established its fiscal year 2026 guidance at $4.540 EPS, with research analysts projecting an EPS of $4.5 for the current year.
Prestige Consumer Healthcare is a prominent manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company specializes in developing and commercializing a diverse range of non-prescription remedies that address various common health needs, including pain relief, cold and cough remedies, digestive health, eye care, skin care, and women’s health. Key brands in its portfolio include Clear Eyes, Carmex, Chloraseptic, Dramamine, Rolaids, Monistat, BC Powder, Little Remedies, and TheraTears.
For ongoing updates and insights into Prestige Consumer Healthcare, interested parties can subscribe to daily summaries of the latest news and analyst ratings through MarketBeat.com.
